NCT01766778View on ClinicalTrials.gov

Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin

PHASE4CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

May 13, 2013

Primary Completion Date

October 22, 2015

Study Completion Date

October 22, 2015

Conditions
Type-2 Diabetes Mellitus
Interventions
DRUG

LAF237 (vildagliptin)

Vildagliptin 50mg capsule

DRUG

Metformin

Metformin maximum tolerance dose

Trial Locations (4)

Unknown

Novartis Investigative Site, Hong Kong

Novartis Investigative Site, Tuenmen

Novartis Investigative Site, Hong Kong

Novartis Investigative Site, Hong Kong SAR

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY